Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.35 -2.9%	$1.29	$1.05 ▼ $10.16	$43.72M	1.65	257,006 shs	213,026 shs
COEP Coeptis Therapeutics	$13.97 +21.7%	$9.63	$2.31 ▼ $14.46	$40.34M	-0.59	55,334 shs	133,586 shs
GLYC GlycoMimetics	$0.16 -6.6%	$13.48	$14.06 ▼ $63.00	$10.00M	1.62	67,672 shs	1.05 million shs
OVID Ovid Therapeutics	$0.97 +15.4%	$0.45	$0.24 ▼ $1.47	$59.75M	0.2	1.70 million shs	4.53 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+6.11%	+9.45%	+8.59%	+20.87%	-80.20%
COEP Coeptis Therapeutics	+5.71%	+8.30%	+16.67%	+17.02%	+171.65%
GLYC GlycoMimetics	0.00%	0.00%	0.00%	-99.37%	-99.11%
OVID Ovid Therapeutics	-2.06%	+64.28%	+128.34%	+177.33%	-16.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.9742 of 5 stars	3.5	3.0	0.0	0.0	2.4	2.5	0.6
COEP Coeptis Therapeutics	0.5173 of 5 stars	0.0	3.0	0.0	0.0	2.0	1.7	0.0
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	4.2407 of 5 stars	3.6	3.0	0.0	4.6	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.57	1,201.59% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
GLYC GlycoMimetics	3.00	Buy	N/A	N/A
OVID Ovid Therapeutics	3.17	Buy	$3.10	219.59% Upside

Current Analyst Ratings Breakdown

Latest GLYC, COEP, ACRV, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
8/8/2025	OVID Ovid Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$4.55 per share	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
OVID Ovid Therapeutics	$570K	121.01	N/A	N/A	$0.78 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.25	N/A	N/A	N/A	N/A	-50.78%	-46.08%	N/A
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-216.96%	-113.00%	N/A
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-574.44%	-58.87%	-43.18%	N/A

Latest GLYC, COEP, ACRV, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	$0.20 million
8/13/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.55	+$0.02	-$0.55	N/A	N/A
8/13/2025	Q2 2025	OVID Ovid Therapeutics	-$0.16	-$0.06	+$0.10	-$0.06	$0.09 million	$6.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	10.31	11.17
COEP Coeptis Therapeutics	0.02	0.82	0.82
GLYC GlycoMimetics	N/A	1.92	1.92
OVID Ovid Therapeutics	0.23	4.72	4.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
COEP Coeptis Therapeutics	13.88%
GLYC GlycoMimetics	75.19%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
COEP Coeptis Therapeutics	24.25%
GLYC GlycoMimetics	8.70%
OVID Ovid Therapeutics	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.46 million	27.62 million	Not Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable

GLYC, COEP, ACRV, and OVID Headlines

Recent News About These Companies

Ovid Therapeutics Reports Increased Revenue Amid Challenges

August 14 at 11:49 AM | msn.com

Ovid Therapeutics Navigates FDA Disruptions and Government Challenges

August 14 at 2:05 AM | tipranks.com

Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating

August 13 at 2:32 PM | tipranks.com

Ovid Therapeutics initiated with a Buy at Lucid Capital

August 13 at 1:08 PM | msn.com

Ovid Therapeutics Transfers Stock to Nasdaq Capital Market

August 13 at 1:08 PM | msn.com

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

August 13 at 10:26 AM | zacks.com

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

August 13 at 8:00 AM | globenewswire.com

Lucid Capital Markets initiates Ovid Therapeutics stock with Buy rating

August 13 at 7:13 AM | investing.com

Amit Rakhit: Global Access, Local Wisdom — How Biotech Thrives Amid Regulatory Complexity

August 13 at 3:06 AM | msn.com

Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

B.Riley assumes coverage on Ovid Therapeutics stock with Buy rating

August 8, 2025 | investing.com

Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma

July 25, 2025 | insidermonkey.com

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

July 23, 2025 | globenewswire.com

Ovid Therapeutics management to meet with B. Riley

July 17, 2025 | msn.com

Ovid woman arrested in Waterloo for driving with suspended license

July 16, 2025 | fingerlakes1.comF

Ovid Therapeutics Approves Key Proposals at Annual Meeting

July 10, 2025 | tipranks.com

Ovid Therapeutics Inc. (OVID) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Ovid Therapeutics Inc Chart - Morningstar

July 2, 2025 | morningstar.comM

Juneberry Farm in Ovid opens for u-pick season

July 1, 2025 | fingerlakes1.comF

Ovid man, 81, charged with DWI after near-crash

June 28, 2025 | fingerlakes1.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLYC, COEP, ACRV, and OVID Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.35 -0.04 (-2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 +0.03 (+2.22%)

As of 07:50 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Coeptis Therapeutics NASDAQ:COEP

$13.97 +2.49 (+21.69%)

Closing price 04:00 PM Eastern

Extended Trading

$13.70 -0.27 (-1.93%)

As of 06:35 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Ovid Therapeutics NASDAQ:OVID

$0.97 +0.13 (+15.43%)

Closing price 04:00 PM Eastern

Extended Trading

$0.97 +0.00 (+0.41%)

As of 07:59 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time